Catalyst Dossier · compiled by CeliA 🧫

Daiichi Sankyo (DSKYF)

Healthcare · market cap $28.8B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Daiichi Sankyo (DSKYF) is a Japanese healthcare company with approximately 19,765 employees and a market capitalization of roughly $28.8 billion. The company fields an extensive pipeline anchored by its antibody-drug conjugate (ADC) platform, with key assets including Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan, Patritumab Deruxtecan, and R-DXd across multiple oncology indications, alongside legacy cardiovascular, metabolic, and anti-infective programs. The nearest high-importance catalysts are Phase 3 readouts for T-DXd and Ramucirumab expected in August 2026.

The catalyst path

2026-08-03 (est.)Phase 3 · T-DXdimp 9/10
2026-08-31 (est.)Phase 3 · Ramucirumabimp 9/10
2026-09-30 (est.)Phase 2 · CS-1008imp 7/10
2026-10-20 (est.)Phase 2 · DS-3939aimp 7/10
2027-01-31 (est.)Phase 2 · DS-5141bimp 7/10
2027-04-30 (est.)Phase 2 · Ifinatamab deruxtecan (I-DXd)imp 7/10
2027-04-30 (est.)Phase 3 · Ifinatamab deruxtecanimp 9/10
2027-04-30 (est.)Phase 3 · Topotecanimp 9/10

Pipeline

Asset	Phase	Indication
CS-7017	Phase 2	Advanced Non-small Cell Lung Cancer (NSCLC)
Dalteparin	Phase 3	Venous Thromboembolism (VTE)
Paclitaxel	Phase 2	Ovarian Cancer Stage IIIC
Patritumab Deruxtecan (Fixed dose)	Phase 2	Non-Small Cell Lung Cancer Metastatic
Carperitide	Phase 2	Heart Failure, Congestive
olmesartan medoxomil + hydrochlorothiazide	Phase 3	Essential Hypertension
DS-5670a	Phase 2	Covid19
cevimeline hydrochloride	Phase 3	Head and Neck Cancer
T-DXd	Phase 3	Advanced Cancer
Quizartinib	Phase 3	Leukemia
DU-176b tablets	Phase 2	Atrial Fibrillation
DS-8201a	Phase 3	Neoplasm, Gastrointestinal
Trastuzumab Deruxtecan	Phase 3	Gastric Cancer
CS-3150	Phase 3	Essential Hypertension
Patritumab Deruxtecan	Phase 3	Nonsquamous Non-small Cell Lung Cancer
soblidotin	Phase 2	Lung Cancer
R-DXd	Phase 3	Solid Cancer
Edoxaban-based Regimen	Phase 3	Atrial Fibrillation
pembrolizumab	Phase 3	Non-small Cell Lung Cancer
DS-8500a 25 mg	Phase 2	Type 2 Diabetes Mellitus

Price & technical context

3-month

-6.9%

6-month

-4.6%

12-month

-18.5%

52-wk range

$20.58–$30.30

vs 50-day MA

-8.5%

vs 200-day MA

-9.4%

Realized vol

79.1%

Max drawdown

-53.8%

Daily closes through 2025-12-22. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DSKYF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.